Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
30.61
-0.22 (-0.71%)
Apr 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 30.50 - 31.00
52 week 19.31 - 31.00
Open 30.83
Vol / Avg. 0.00/250,493.00
Mkt cap 1.17B
P/E 63.24
Div/yield     -
EPS 0.48
Shares 38.32M
Beta 1.05
Inst. own 80%
May 22, 2015
Emergent BioSolutions Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Emergent BioSolutions Inc Earnings Call - 5:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Emergent BioSolutions Inc Earnings Release - 4:00PM EDT - Add to calendar
May 6, 2015
Emergent BioSolutions Inc at Credit Suisse Antibody Day - 1:50PM EDT - Add to calendar
Mar 26, 2015
Emergent BioSolutions Inc at Maidstone Life Sciences Cancer Immunotherapy: A Long-Awaited Reality Conference
Mar 10, 2015
Emergent BioSolutions Inc at Credit Suisse Under Followed Opportunities Conference
Mar 5, 2015
Q4 2014 Emergent BioSolutions Inc Earnings Call - Webcast
Mar 5, 2015
Q4 2014 Emergent BioSolutions Inc Earnings Release
Mar 2, 2015
Emergent BioSolutions Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 20.35% 8.16%
Operating margin 30.15% 12.90%
EBITD margin - 20.11%
Return on average assets 13.31% 4.67%
Return on average equity 22.66% 7.05%
Employees 1,280 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense division and BioSciences division. The BioDefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or bio-warfare and targets the infectious disease, anthrax. Its programs include a pipeline of investigational product candidates and one marketed product, BioThrax (Anthrax Vaccine Adsorbed). The Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. Its products include WinRho SDF, HepaGam B, VARIZIG and Episil.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 57
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 44
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 51
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 63
Bio & Compensation  - Reuters
George A. Joulwan Independent Director
Age: 75
Bio & Compensation  - Reuters